December 1, 2020 06:23 AM ESTUpdated 07:30 AM

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Amber Tong

As the former head of neuroscience product development at Roche for a decade, George Garibaldi can personally vouch for the quality of what the Swiss …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Amber Tong

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Roche shelved these psy­chi­a­try drugs. So its for­mer head of neu­ro cooked up some new plans — and raised $59M for his start­up

Amber Tong

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers